Citation:Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012
From Cancer Guidelines Wiki
Citation
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 Jul 12;367(2):107-14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22663011.
Critical appraisals
Compare quality appraisals for each clinical question
- [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span>»]] (compare critical appraisals)
- [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span></span>»]] (compare critical appraisals)